Comparative Two-Year Drug Survival of Bimekizumab and Brodalumab in Second-Line Treatment of Psoriasis.

Bimzelx (bimekizumab-bkzx) - UCB

Siliq (brodalumab) - Bausch Health

http://www.ncbi.nlm.nih.gov/pubmed/42036018

Christoffer Valdemar Nissen; Christopher Willy Schwarz; Kasper Fjellhaugen Hjuler; Lars Erik Bryld; Lone Skov; Mads Kirchheiner Rasmussen; Mathias Tiedemann Svendsen; Nikolai Loft; Tomas Norman Dam; Trine Bertelsen

Apr 27, 2026